A detailed history of Morgan Stanley transactions in Pharvaris N.V. stock. As of the latest transaction made, Morgan Stanley holds 24,251 shares of PHVS stock, worth $456,646. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,251
Previous 23,296 4.1%
Holding current value
$456,646
Previous $437,000 2.75%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.73 - $21.4 $15,022 - $20,437
955 Added 4.1%
24,251 $449,000
Q2 2024

Oct 17, 2024

SELL
$15.67 - $24.59 $90,024 - $141,269
-5,745 Reduced 19.78%
23,296 $437,000
Q2 2024

Aug 14, 2024

SELL
$15.67 - $24.59 $90,024 - $141,269
-5,745 Reduced 19.78%
23,296 $437,000
Q1 2024

Oct 17, 2024

BUY
$21.26 - $32.07 $122,138 - $184,242
5,745 Added 24.66%
29,041 $671,000
Q1 2024

Aug 16, 2024

BUY
$21.26 - $32.07 $139,316 - $210,154
6,553 Added 29.14%
29,041 $671,000
Q1 2024

May 15, 2024

BUY
$21.26 - $32.07 $139,316 - $210,154
6,553 Added 29.14%
29,041 $671,000
Q4 2023

Aug 16, 2024

SELL
$15.2 - $28.05 $12,281 - $22,664
-808 Reduced 3.47%
22,488 $630,000
Q4 2023

Feb 13, 2024

SELL
$15.2 - $28.05 $170,376 - $314,412
-11,209 Reduced 33.26%
22,488 $630,000
Q3 2023

Nov 15, 2023

SELL
$14.68 - $21.4 $170,801 - $248,988
-11,635 Reduced 25.67%
33,697 $703,000
Q2 2023

Aug 14, 2023

SELL
$7.82 - $16.0 $28,566 - $58,448
-3,653 Reduced 7.46%
45,332 $686,000
Q1 2023

May 15, 2023

BUY
$6.34 - $12.27 $68,503 - $132,577
10,805 Added 28.3%
48,985 $394,000
Q4 2022

Feb 14, 2023

BUY
$1.98 - $11.46 $37,788 - $218,714
19,085 Added 99.95%
38,180 $429,000
Q3 2022

Nov 14, 2022

BUY
$7.67 - $25.8 $17,479 - $58,798
2,279 Added 13.55%
19,095 $146,000
Q2 2022

Oct 27, 2022

BUY
$16.35 - $27.5 $10,316 - $17,352
631 Added 3.9%
16,816 $372,000
Q2 2022

Aug 15, 2022

BUY
$16.35 - $27.5 $10,316 - $17,352
631 Added 3.9%
16,816 $372,000
Q1 2022

Oct 27, 2022

SELL
$15.98 - $19.65 $10,083 - $12,399
-631 Reduced 3.75%
16,185 $294,000
Q1 2022

May 13, 2022

SELL
$15.98 - $19.65 $33,094 - $40,695
-2,071 Reduced 11.34%
16,185 $294,000
Q4 2021

Feb 14, 2022

BUY
$13.28 - $18.0 $9,415 - $12,762
709 Added 4.04%
18,256 $262,000
Q3 2021

Nov 15, 2021

BUY
$13.14 - $20.97 $230,567 - $367,960
17,547 New
17,547 $311,000

Others Institutions Holding PHVS

About Pharvaris N.V.


  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $636M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.